The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis

Gao, Yongquan; Liu, Xiaochen; Gu, Yuan; Song, Deye; Ding, Muliang; Liao, Lele; Wang, Junjie; Ni, Jiangdong; He, Guangxu

doi:10.3389/fendo.2021.688269

Cited by 28 publications

(24 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Early keyword co-occurrence analysis found that alendronate was the most frequently used in clinical use. According to the most citations of 50 articles in recent 2 years, zoledronic acid was used most frequently, which was consistent with the results of Gao et al [ 38 ]. After long-term bisphosphonate medication, patients with osteoporosis will re-evaluate the appropriate response.…”

Section: Discussionsupporting

confidence: 89%

Bisphosphates for Osteoporosis: A Bibliometric Analysis of the Most Cited Articles

Zhang

Zhu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Osteoporosis has become a major public health problem and bisphosphates treatment for osteoporosis is a rapidly developing research field. Every year, plenty of studies devoted to the treatment of osteoporosis are published, giving clinicians a new perspective on bisphosphates treatment for osteoporosis. However, the quality of the scientific papers in this area is unclear. The aim of the present study was to characterize the 100 top-cited articles regarding bisphosphates treatment for osteoporosis. This analysis provides an accessible list for practitioners of endocrinology, pharmacy, epidemiology, imaging, surgery, and scientific research to identify the most frequently cited literature and better understand the future direction.

show abstract

Section: Discussionsupporting

confidence: 89%

Bisphosphates for Osteoporosis: A Bibliometric Analysis of the Most Cited Articles

Zhang

Zhu

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Pooled analysis of the timing studies also did not show any significant difference in fracture healing time between early (<1 month) and late (>1 month) bisphosphonate initiation following surgery [two studies; MD: −0.20, 95% CI: −1.03 to 0.63; p = 0.64]. Gao et al 42 also did not find any significant difference in fracture healing time between the bisphosphonate and the pooled comparator group [five studies; SMD: 0.17, 95% CI: −0.09 to 0.42; p = 0.21]. However, in their meta-analysis, studies with prior bisphosphonate use were analyzed together along with the studies where it had been initiated after surgery.…”

Section: Effect Of Timing Of Therapy On Fracture Healingmentioning

confidence: 96%

“…In another meta-analysis by Xue et al, 40 42 also did not find any significant difference in fracture healing time between the bisphosphonate and the pooled comparator group [five studies; SMD: 0.17, 95% CI: −0.09 to 0.42; p = 0.21]. However, in their meta-analysis, studies with prior bisphosphonate use were analyzed together along with the studies where it had been initiated after surgery.…”

Section: Effect Of Timing Of Therapy On Fracture Healingmentioning

confidence: 96%

See 1 more Smart Citation

Timing of osteoporosis therapies following fracture: the current status

Palui

Durgia

Sahoo

et al. 2022

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

In most patients, osteoporosis is diagnosed only after the occurrence of the first fragility fracture. It is of utmost importance to start osteoporosis medications immediately in these patients to prevent future fractures and also to reduce associated mortality and morbidity. There remains a hesitancy over initiating osteoporotic medications, specifically for antiresorptive agents like bisphosphonates following an acute fracture due to concern over their effect on fracture healing. The purpose of this review is to study the effect of the timing of initiation of different osteoporosis medications on healing after an acute fracture. Most of the human studies, including randomized control trials (RCTs), did not find any significant negative effect on fracture healing with early use of bisphosphonate after an acute fracture. Anabolic agents like teriparatide have shown either neutral or beneficial effects on fracture healing and thus can be started very early following any osteoporotic fracture. Although human studies on the early use of other osteoporosis medications like denosumab or strontium ranelate are very sparse in the literature, none of these medications have shown any evidence of delay in fracture healing. To summarize, among the commonly used anti-osteoporosis agents, both bisphosphonates and teriparatide are safe to be initiated in the early acute post-fracture period. Moreover, teriparatide has shown some evidence in favor of reducing fracture healing time.

show abstract

“…В метаанализе 16 клинических исследований, включивших 5 022 больных остеопорозом с переломами и остеотомиями, отмечено отсутствие отрицательного влияния БФ на скорость сращения переломов, что дает основание рекомендовать их назначение в послеоперационном периоде [44].…”

Section: эффективность золедроновой кислоты после переломов у больных...unclassified

Zoledronic acid for osteoporosis and associated low-energy fractures

et al. 2022

View full text Add to dashboard Cite

Zoledronic acid is a third-generation amino-containing BF that has been used to treat patients with osteoporosis for more than 15 years. Over the years, numerous experimental and clinical studies have proven the high efficacy of the drug in osteoporosis, both in women of various age groups, and in men, with primary and secondary osteoporosis, in patients with varying degrees of bone loss and risk of fractures. Intravenous infusions of zoledronic acid have been shown to result in a rapid gain of bone mass, a significant reduction in the risk of low-energy fractures of the vertebrae (spine), proximal femoral and nonvertebral fractures on the whole. However, in recent years, the use of the drug has significantly decreased, which is associated both with the lack of awareness of primary care physicians about the possibilities of this drug, and the fear of such complications of its use as atypical fractures and osteonecrosis of the jaw bones. The presented review aims to increase the knowledge of physicians regarding the mechanism of action of zoledronic acid, the regimens for prescribing the drug in various forms of osteoporosis and fractures against its background. The given clinical example shows the ability of zoledronic acid (osteostatics) to increase the mass of not only cancellous, but also the cortical bone of the proximal femur, which increases the role of zoledronic acid in the prevention of recurrent fractures. On top of that, the prolonged effect of the drug allows, when the desired therapeutic effect is achieved, to reduce the frequency of prescribing according to the ‘drug holiday’ principal, decreasing economic expenditures and medical and social burden.

show abstract

The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis

Cited by 28 publications

References 66 publications

Bisphosphates for Osteoporosis: A Bibliometric Analysis of the Most Cited Articles

Bisphosphates for Osteoporosis: A Bibliometric Analysis of the Most Cited Articles

Timing of osteoporosis therapies following fracture: the current status

Zoledronic acid for osteoporosis and associated low-energy fractures

Contact Info

Product

Resources

About